Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT/A)

PLoS Pathogens

Volumn 9, Issue 5, 2013, Pages

  Jacky, Birgitte P S ^a   Garay, Patton E ^a   Dupuy, Jérôme ^b,c   Nelson, Jeremy B ^a   Cai, Brian ^a   Molina, Yanira ^a   Wang, Joanne ^a   Steward, Lance E ^a   Broide, Ron S ^a   Francis, Joseph ^a   Aoki, K Roger ^a   Stevens, Raymond C ^b   Fernández Salas, Ester ^a  

^a ALLERGAN INC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR 3; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BLEACHING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIGAND BINDING; NERVE CELL; NONHUMAN; PARALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

ANIMALS; BOTULINUM TOXINS, TYPE A; CELL MEMBRANE; HEK293 CELLS; HUMANS; MICE; PC12 CELLS; PROTEIN TRANSPORT; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

EID: 84878505471     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003369     Document Type: Article

References (73)

1. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365: 160-163 10.1038/365160a0 [doi].
2. Montecucco C, Papini E, Schiavo G, (1994) Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett 346: 92-98.
3. Keller JE, Cai F, Neale EA, (2004) Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43: 526-532.
4. Verderio C, Grumelli C, Raiteri L, Coco S, Paluzzi S, et al. (2007) Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8: 142-153.
5. Popoff MR, Poulain B, (2010) Bacterial Toxins and the Nervous System: Neurotoxins and Multipontetial Toxins Interacting with Neuronal Cells. Toxins 2: 683-737.
6. Schulte-Mattler WJ, (2008) Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs 22: 725-738.
7. Apostolidis A, Fowler CJ, (2008) The use of botulinum neurotoxin type A (BoNTA) in urology. J Neural Transm 115: 593-605.
8. Montal M, (2010) Botulinum Neurotoxin: A Marvel of Protein Design. Annual Review of Biochemistry 79: 591-617.
9. Burstein R, Dodick D, Silberstein S, (2009) Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon 54: 624-627 S0041-0101(09)00042-7 [pii];10.1016/j.toxicon.2009.01.009 [doi].
10. Schieman C, Gelfand GJ, Grondin SC, (2010) Hyperhidrosis: clinical presentation, evaluation and management. Expert Rev Dermatol 5: 31-44.
11. Dolly JO, Black J, Williams RS, Melling J, (1984) Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 307: 457-460.
12. Montecucco C, (1986) How do Tetanus and Botulinum toxins to neuronal membranes? Trends Biochem Sci 11: 315-317.
13. Montecucco C, Rossetto O, Schiavo G, (2004) Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol 12: 442-446.
14. Rummel A, Mahrhold S, Bigalke H, Binz T, (2004) The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51: 631-643.
15. Stenmark P, Dupuy J, Imamura A, Kiso M, Stevens RC, (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog 4: e1000129 10.1371/journal.ppat.1000129 [doi].
16. Yowler BC, Schengrund CL, (2004) Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. Biochemistry 43: 9725-9731.
17. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T, (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580: 2011-2014.
18. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596.
19. Verderio C, Rossetto O, Grumelli C, Frassoni C, Montecucco C, et al. (2006) Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep 7: 995-999.
20. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, et al. (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19: 5226-5237.
21. Baldwin MR, Barbieri JT, (2009) Association of botulinum neurotoxins with synaptic vesicle protein complexes. Toxicon 54: 570-574.
22. Rummel A, Hafner K, Mahrhold S, Darashchonak N, Holt M, et al. (2009) Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J Neurochem 110: 1942-1954.
23. Rummel A, (2013) Double Receptor Anchorage of Botulinum Neurotoxins Accounts for their Exquisite Neurospecificity. Curr Top Microbiol Immunol 364: 61-90 10.1007/978-3-642-33570-9_4 [doi].
24. Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR, (2009) Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48: 5631-5641.
25. Strotmeier J, Lee K, Volker AK, Mahrhold S, Zong Y, et al. (2010) Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem J 431: 207-216 BJ20101042 [pii];10.1042/BJ20101042 [doi].
26. Peng L, Tepp WH, Johnson EA, Dong M, (2011) Botulinum Neurotoxin D Uses Synaptic Vesicle Protein SV2 and Gangliosides as Receptors. PLoS Pathog 7: e1002008 10.1371/journal.ppat.1002008 [doi].
27. Yeh FL, Dong M, Yao J, Tepp WH, Lin G, et al. (2010) SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog 6: e1001207 10.1371/journal.ppat.1001207 [doi].
28. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC, (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5: 898-902.
29. Lacy DB, Stevens RC, (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291: 1091-1104 S0022-2836(99)92945-5 [pii];10.1006/jmbi.1999.2945 [doi].
30. Keegan K, Johnson DE, Williams LT, Hayman MJ, (1991) Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci U S A 88: 1095-1099.
31. Keegan K, Meyer S, Hayman MJ, (1991) Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 6: 2229-2236.
32. Webster MK, Donoghue DJ, (1996) Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15: 520-527.
33. Webster MK, D'Avis PY, Robertson SC, Donoghue DJ, (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16: 4081-4087.
34. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, et al. (2000) Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19: 3309-3320 10.1038/sj.onc.1203650 [doi].
35. Beenken A, Mohammadi M, (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253 nrd2792 [pii];10.1038/nrd2792 [doi].
36. Johnson DE, Lu J, Chen H, Werner S, Williams LT, (1991) The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 11: 4627-4634.
37. Werner S, Duan DS, de VC, Peters KG, Johnson DE, Williams LT, (1992) Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 12: 82-88.
38. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM, (1994) Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 269: 11620-11627.
39. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, et al. (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281: 15694-15700.
40. Sturla LM, Merrick AE, Burchill SA, (2003) FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br J Cancer 89: 1276-1284 10.1038/sj.bjc.6601249 [doi];6601249 [pii].
41. Champion-Arnaud P, Ronsin C, Gilbert E, Gesnel MC, Houssaint E, et al. (1991) Multiple mRNAs code for proteins related to the BEK fibroblast growth factor receptor. Oncogene 6: 979-987.
42. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, et al. (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem 271: 15292-15297.
43. Rusnati M, Urbinati C, Tanghetti E, Dell'Era P, Lortat-Jacob H, et al. (2002) Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proc Natl Acad Sci U S A 99: 4367-4372.
44. Toledo MS, Suzuki E, Handa K, Hakomori S, (2005) Effect of ganglioside and tetraspanins in microdomains on interaction of integrins with fibroblast growth factor receptor. J Biol Chem 280: 16227-16234.
45. Eswarakumar VP, Lax I, Schlessinger J, (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149 S1359-6101(05)00002-X [pii];10.1016/j.cytogfr.2005.01.001 [doi].
46. West DC, Rees CG, Duchesne L, Patey SJ, Terry CJ, et al. (2005) Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem 280: 13457-13464.
47. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, et al. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123.
48. Hu Y, Guimond SE, Travers P, Cadman S, Hohenester E, et al. (2009) Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein anosmin-1. J Biol Chem 284: 29905-29920.
49. Greene LA, Tischler AS, (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 73: 2424-2428.
50. Puffer EB, Lomneth RB, Sarkar HK, Singh BR, (2001) Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process. Biochemistry 40: 9374-9378.
51. Olsen SK, Garbi M, Zampieri N, Eliseenkova AV, Ornitz DM, et al. (2003) Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 278: 34226-34236 10.1074/jbc.M303183200 [doi];M303183200 [pii].
52. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, et al. (2004) Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A 101: 935-940.
53. Nishiki T, Kamata Y, Nemoto Y, Omori A, Ito T, et al. (1994) Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 269: 10498-10503.
54. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, et al. (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162: 1293-1303 10.1083/jcb.200305098 [doi];jcb.200305098 [pii].
55. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, et al. (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444: 1096-1100 nature05411 [pii];10.1038/nature05411 [doi].
56. Jin R, Rummel A, Binz T, Brunger AT, (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444: 1092-1095.
57. Li S, Christensen C, Kohler LB, Kiselyov VV, Berezin V, et al. (2009) Agonists of fibroblast growth factor receptor induce neurite outgrowth and survival of cerebellar granule neurons. Dev Neurobiol 69: 837-854 10.1002/dneu.20740 [doi].
58. Purkiss JR, Friis LM, Doward S, Quinn CP, (2001) Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology 22: 447-453.
59. Wiedlocha A, Sorensen V, (2004) Signaling, internalization, and intracellular activity of fibroblast growth factor. Curr Top Microbiol Immunol 286: 45-79.
60. Hughes R, Whaler BC, (1962) Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol 160: 221-233.
61. Habermann E, Dreyer F, Bigalke H, (1980) Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn Schmiedebergs Arch Pharmacol 311: 33-40.
62. Black JD, Dolly JO, (1986) Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 103: 535-544.
63. Restani L, Giribaldi F, Manich M, Bercsenyi K, Menendez G, et al. (2012) Botulinum neurotoxins a and e undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 8: e1003087 10.1371/journal.ppat.1003087 [doi];PPATHOGENS-D-12-00849 [pii].
64. Simpson LL, (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212: 16-21.
65. Duchesne L, Octeau V, Bearon RN, Beckett A, Prior IA, et al. (2012) Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate. PLoS Biol 10: e1001361 10.1371/journal.pbio.1001361 [doi];PBIOLOGY-D-11-03009 [pii].
66. Yowler BC, Kensinger RD, Schengrund CL, (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem 277: 32815-32819.
67. Kitamura M, Takamiya K, Aizawa S, Furukawa K, Furukawa K, (1999) Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. Biochim Biophys Acta 1441: 1-3 S1388-1981(99)00140-7 [pii].
68. Elias M, Al-Saleem F, Ancharski DM, Singh A, Nasser Z, et al. (2011) Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J Pharmacol Exp Ther 336: 605-612 jpet.110.175018 [pii];10.1124/jpet.110.175018 [doi].
69. Wuechner C, Nordqvist AC, Winterpacht A, Zabel B, Schalling M, (1996) Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse. Int J Dev Biol 40: 1185-1188.
70. Fon TK, Bookout AL, Ding X, Kurosu H, John GB, et al. (2010) Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24: 2050-2064 me.2010-0142 [pii];10.1210/me.2010-0142 [doi].
71. Bajjalieh SM, Peterson K, Linial M, Scheller RH, (1993) Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A 90: 2150-2154.
72. Janz R, Sudhof TC, (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94: 1279-1290.
73. Mohammadi M, Olsen SK, Ibrahimi OA, (2005) Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16: 107-137.